Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norflo Oro in HLA-B27 Associated Autoimmune Uveitis
NCT03584724Phase 1Completed
- Sponsor
- Eye Pharma
- Start
- Dec 2018
- Primary completion
- Aug 2020
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial (2 arms), sponsored by Eye Pharma. Primary endpoint: Change in Mean Number of Uveitis Relapses Per Patient at 12 months. Started Dec 2018; status: completed.
Beyond the preview
Go deeper on NCT03584724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03584724.